The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects

Thrombosis and Haemostasis

Volumn 96, Issue 5, 2006, Pages 623-629

  Pieters, Marlien ^a   Covic, Namukolo ^a   Loots, Du Toit ^a   van der Westhuizen, Francois H ^a   van Zyl, Danie G ^b   Rheeder, Paul ^b   Jerling, Johann C ^a   Weisel, John W ^c  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diabetes; Fibrin network structure; Fibrinogen; Glucose control; Glycation

Indexed keywords

FIBRIN; FIBRINOGEN; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FIBRINOGEN BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD COAGULATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIN; FIBRINOGEN; GLYCOSYLATION; HUMANS; INSULIN; MALE; MIDDLE AGED; POROSITY;

EID: 33751218016     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0390     Document Type: Article

References (33)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979; 241: 2035-8.
2. Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 2004; 29: 470-9.
3. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-809.
4. Koenig W Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-9.
5. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000;20:1354-1361.
6. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-206.
7. Nair CH, Azhar A, Wilson JD, et al. Studies on fibrin network structure in human plasma. Part II - Clinical application: diabetes and antidiabetic drugs. Thromb Res 1991; 64: 477-85.
8. Jorneskog G, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39:1519-23.
9. Lutjens A, te Velde AA, vd Veen EA, et al. Glycosylation of human fibrinogen in vivo. Diabetologia 1985;28:87-9.
10. Hammer MR, John PN, Flynn MD, et al. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989; 26: 58-62.
11. Ardawi MS, Nasrat HN, Mira SA, et al. Comparison of glycosylated fibrinogen, albumin, and haemoglobin as indices of blood glucose control in diabetic patients. Diabet Med 1990; 7: 819-24.
12. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983; 32: 680-4.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
14. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
15. Takebe M, Soe G, Kohno I, et al. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 1995; 73: 662-7.
16. Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
17. Fatah K, Hamsten A, Blomback B, et al. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-5.
18. Dhall TZ, Bryce WA, Dhall DP. Effects of dextran on the molecular structure and tensile behaviour of human fibrin. Thromb Haemost 1976; 35: 737-45.
19. Ford I, Singh TP, Kitchen S, et al. Activation of coagulation in diabetes mellitus in relation to the presence ofvascular complications. Diabet Med 199 1; 8: 322-9.
20. Festa A, D'Agostino I, Jr., Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI- 1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vase Biol 1999; 19: 562-8.
21. Donders SH, Lustermans FA, van Wersch JW. Glycometabolic control, lipids, and coagulation parameters in patients with non-insulin-dependent diabetes mellitus. Int J Clin Lab Res 1993; 23: 155-9.
22. Avellone G, Di G, V, Cordova R, et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res 1994; 25: 85-92.
23. Asakawa H, Tokunaga K, Kawakami F. Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. J Diabetes Complications 2000;14:121-6.
24. Jerling JC, Vorster HH, Oosthuizen W, et al. Differences in plasminogen activator inhibitor 1 activity between blacks and whites may be diet related. Haemostasis 1994; 24: 364-8.
25. Folsom AR, Wu KK, Conlan MG, et al. Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis 1992; 2: 35-46.
26. Kannel WB, D'Agostino RB, Wilson PW et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120: 672-6.
27. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-50.
28. Missov RM, Stolk RP, van der Bom JG, et al. Plasma fibrinogen in NIDDM: the Rotterdam study. Diabetes Care 1996; 19: 157-9.
29. Jorneskog G, Hansson LO, Wallen NH, et al, Increased plasma fibrin get porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-201.
30. Ryan EA, Mockros LF, Weisel JW, et al. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-26.
31. Lutjens A, Jonkhoff-Slok TW, Sandkuijl C, et al. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988; 31: 825-30.
32. Ney KA, Pasqua JJ, Colley KJ, et al. In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. Diabetes 1985; 34: 462-70.
33. Austin GE, Mullins RH, Morin LG. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. Clin Chem 1987; 33: 2220-4.